New Cancer Blood Test to be developed by J&J and Massachusetts General Hospital

By on Jan 4, 2011 in Health, United States Comments

A new cancer blood test will be developed by Johnson and Johnson (J&J) and the Massachusetts General Hospital (MGH), and will focus on next-generation Circulating Tumor Cell (CTC) technology to used as an early detection tool for tumor cells that may be found on a patient’s blood.

According to J&J‘s official website on Monday, Veridex, a company of Johnson and Johnson, announced collaboration with Massachusetts General Hospital to develop and commercialized a blood test that could find a single cancer cell circulating in a person’s blood.

The announcement apparently mentioned that the research will involve Biotech Oncology Research and Development, which is a unit of Johnson and Johnson Pharmaceutical Research and Development.

Once the research will be successful, this new cancer blood test will be used by oncologists to detect or discover as early as possible if a cancer has spread, as well as by researchers to come up with new drug therapies for cancer patients.

“This new technology has the potential to facilitate an easy-to-administer, non-invasive blood test that would allow us to count tumor cells and to characterize the biology of the cells.” Veridex’ Technology Innovation and Strategy head Robert McCormack said.

“Harnessing the information contained in these cells in an in vitro clinical setting could enable tools to help select treatment and monitor how patients are responding.” Mr. McCormack added.

“The challenging goal of sorting extremely rare circulating tumor cells from blood requires continuous technological, biological and clinical innovation to fully explore the utility of these precious cells in clinical oncology.” BioMicroElectroMechanical Systems Resource Center in the MGH Center for Engineering in Medicine director Mehmet Toner, Ph.D. said on the report.

“We have developed and continue to develop a broad range of technologies that are evolving what we know about cancer and cancer care. This collaboration is an opportunity to apply our past learning to the advancement of a platform that will ultimately benefit patients with cancer.” Dr. Toner added.

Incidentally, Veridex launched the first commercial CTC test in 2004 and was said to have demonstrated to innovate an advanced CTC testing.



Spread The News!



Tags: , , , , , , , ,

Advertisement

Related News



What's On Your Mind?




Pinterest
Email